Díaz, Natalia Ade Miguel, RosaAgüero, FernandoSued, OmarArribas, José RAmbriosioni, JuanHospital Clinic COVID-19 in HIV Investigators2024-05-232024-05-232021-08https://doi.org/10.1007/s40121-021-00547-yhttps://repositorio.huesped.org.ar/handle/123456789/1301Fil: Díaz NA. Infectious Diseases Service, Hospital Cuenca Alta, Cañuelas; ArgentinaThe HIV pandemic has led to close to 40 million people living with HIV (PLWH) worldwide. To date, SARS-CoV2 has affected > 220 million people, and unprecedented global efforts have resulted in almost 6000 million doses of SARS-CoV2 vaccines being administered. Although several specific COVID-19 antiviral and anti-inflammatory treatments and SARS-CoV2 vaccines have been approved, the data available to support their use in specific populations such as PLWH remain limited. PLWH includes a range of individuals from practically unaffected immunity to severely immunocompromised individuals, and preventive and therapeutic interventions should be tailored for these subgroups . However, in most randomized clinical trials regarding antivirals, immunomodulators and vaccines for COVID-19, PLWH have been excluded or only enrolled in small numbers leading to a paucity of data. We briefly discuss the current evidence for prevention and treatment of COVID-19 in PLWH and identify key areas where more information is required.application/pdfopenAccessCOVID-19VIHInfecciones por VIHSARS-CoV-2Vacunas contra la COVID-19TerapéuticaArticulo